Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ex vivo profiling of PD-1 blockade using MDOTS

Published byThalita Conceição Modified over 4 years ago

Similar presentations

Presentation on theme: "Ex vivo profiling of PD-1 blockade using MDOTS"— Presentation transcript:

1 Ex vivo profiling of PD-1 blockade using MDOTS
Ex vivo profiling of PD-1 blockade using MDOTS. A, Schematic of MDOTS live/dead imaging workflow. Ex vivo profiling of PD-1 blockade using MDOTS. A, Schematic of MDOTS live/dead imaging workflow. B, MC38 implanted tumor volume (TV) following isotype control IgG (n = 10) or rat–anti-mouse anti–PD-1 antibody (n = 10) treatment (mean ± SEM, two-way ANOVA, Sidak multiple comparison test; **, P < 0.01; ****, P < ). C, Live (AO = green)/dead (PI = red) quantification of MC38 MDOTS day 0 (immediately after loading), day 3, and day 6 following IgG control or indicated anti–PD-1 antibody doses (n = 4, biological replicates, two-way ANOVA with Dunnett with multiple comparisons test; **, P < 0.01; ****, P < ). D, Live/dead analysis of MC38 spheroids lacking immune cells ± anti–PD-1 (n = 4, biological replicates). E, Live/dead analysis of B16F10 MDOTS ± anti–PD-1 (n = 3, biological replicates). F, Deconvolution fluorescence microscopy of MC38 and B16F10 MDOTS day 6 ± anti–PD-1 (representative images shown). G, Live/dead analysis of CT26 MDOTS ± anti–PD-1 (n = 3, biological replicates, two-way ANOVA with Dunnett with multiple comparisons test; ****, P < ). H, Live/dead analysis of CT26 MDOTS performed on day 6 following treatment with isotype IgG control (10 μg/mL) or anti–PD-1 (10 μg/mL) ± anti-CD8 (10 μg/mL; n = 6, biological replicates; two-way ANOVA with Tukey multiple comparisons test; ****, P < ; ns = not significant). I, CT26 TVs for responder (R1 + R2) and nonresponder (NR1 + NR2) BALB/c mice treated with anti–PD-1 (10 mg/kg twice weekly × 6 doses, starting at day 5) with time of tumor harvest for MDOTS preparation indicated (*). J, Live/dead analysis (day 6) of CT26 MDOTS from responder and nonresponder mice following ex vivo treatment with isotype IgG control (10 μg/mL) or anti–PD-1 (10 μg/mL; n = 3, biological replicates; two-way ANOVA with Tukey multiple comparisons test; ***, P < 0.001; ns = not significant). Russell W. Jenkins et al. Cancer Discov 2018;8: ©2018 by American Association for Cancer Research

Download ppt "Ex vivo profiling of PD-1 blockade using MDOTS"

Similar presentations

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.

Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.
Sialylated Ab-ICs promote enhanced humoral immune responses.

Sialylated Ab-ICs promote enhanced humoral immune responses.
by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.
Fig. 5 Local gel scaffold for T cell memory response.

Fig. 5 Local gel scaffold for T cell memory response.
Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.
Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.
Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.
Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
In vivo growth inhibition elicited by afatinib and GSK2849330 in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.
PD-1 blockade results in increased expression of the chemokine receptor CXCR3. PD-1 blockade results in increased expression of the chemokine receptor.

PD-1 blockade results in increased expression of the chemokine receptor CXCR3. PD-1 blockade results in increased expression of the chemokine receptor.

Similar presentations

Ads by Google